ArticleApplied biochemistry and biotechnology2026
Investigation of the In Vitro Neuroprotective Potential of Aegiceras corniculatum against MPTP-induced Toxicity.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aegiceras corniculatum (AC), a mangrove species widely recognized for its diverse pharmacological properties, has attracted significant attention recently due to its antioxidant, anti-inflammatory, and antimicrobial activities. Despite this, the neuroprotective potential of AC, particularly in the context of neurodegenerative disorders such as Parkinson's disease (PD), remains largely unexplored. Due to the growing interest in plant-derived compounds for the management of PD, investigating the therapeutic relevance of AC could provide new insights into alternative strategies for neuroprotection. The present study aimed to evaluate the neuroprotective ability of the leaf extract of AC against PD. Preliminary phytochemical analyses were conducted to identify the presence of bioactive compounds in the AC extract (ACE). The antioxidant capacity of ACE was evaluated using three standard assays: 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assay, ferric reducing antioxidant power (FRAP) assay, and hydrogen peroxide (H₂O₂) scavenging assay. We used the MPTP-induced PD model established in an SH-SY5Y human neuroblastoma cell line as well as in the U87-MG glioblastoma cell line. MTT assay was conducted to measure the cell viability, and further, 2',7'-dichlorofluorescin diacetate (DCFDA) assay was used to measure the reactive oxygen species (ROS). Glutathione peroxidase (GPx) enzyme activity was determined by a chromogenic reaction-based assay. Western blot analysis was used to assess the expression levels of SNCA protein. The ACE was found to contain a diverse range of phytochemicals, including polyphenols, flavonoids, and terpenoids. Among the ethanolic, hydroethanolic, and aqueous extracts evaluated, ethanolic ACE (eACE) exhibited the highest antioxidant activity. The SH-SY5Y cell line demonstrated significantly higher neuroprotective potential to eACE treatment compared to the U87-MG cell line. Moreover, eACE markedly attenuated intracellular ROS levels and enhanced glutathione peroxidase (GP
Indexed as
Identifiers
41543687What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.